Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company, will participate in the 4th Annual Evercore ISI HealthCONx Conference from November 30 to December 2, 2021. Mark A. Goldsmith, M.D., Ph.D., CEO and chairman, will join a fireside chat on December 2 at 11:45 a.m. Eastern. The event will be virtual, with a live webcast available on Revolution Medicines’ website, where a replay will be accessible for 14 days post-conference. The company focuses on developing targeted therapies for RAS-addicted cancers, with various RAS(ON) and Companion Inhibitors in its R&D pipeline.

REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the 4^th Annual Evercore ISI HealthCONx Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Details of the company’s participation are as follows:

• 4^th Annual Evercore ISI HealthCONx Conference
  Conference Date: November 30 – December 2, 2021
  Fireside Chat Time/Date: 11:45 a.m. Eastern on Thursday, December 2, 2021
  Format: Virtual conference; webcast available        

To access the live webcast of the fireside chat, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

FAQ

What is Revolution Medicines discussing at the Evercore ISI HealthCONx Conference?

Revolution Medicines will discuss its developments in precision oncology and targeted therapies during the 4th Annual Evercore ISI HealthCONx Conference.

When will Revolution Medicines' fireside chat take place?

The fireside chat with Revolution Medicines' CEO is scheduled for December 2, 2021, at 11:45 a.m. Eastern.

How can I access the webcast of the Revolution Medicines events?

The webcast can be accessed through the 'Events & Presentations' page on Revolution Medicines' website.

What is the focus of Revolution Medicines' drug development?

Revolution Medicines focuses on creating targeted drugs for RAS-addicted cancers, including RAS(ON) Inhibitors and RAS Companion Inhibitors.

What are some compounds in Revolution Medicines' R&D pipeline?

The R&D pipeline includes RMC-6291, RMC-6236 as RAS(ON) Inhibitors, and RMC-4630, RMC-5552, and RMC-5845 as RAS Companion Inhibitors.